Medartis Holding AG
SIX:MED
Medartis Holding AG
Medartis Holding AG operates as a medical device company. The company is headquartered in Basel, Basel-Stadt and currently employs 684 full-time employees. The company went IPO on 2018-03-23. The Group develops, manufactures and distributes to surgeons, hospitals and medical centers titanium screws, plates, surgical instruments and system solutions for internal fracture fixation. Medartis AG, the Company's wholly-owned subsidiary, has developed such technologies as TriLock for locking the screw into the plate, SpeedTip, a screw that does not require pre-drilling, and HexaDrive self-holding screw and screw-driver. The company has two product lines. The APTUS product line comprises upper and lower extremities products for hand, wrist, elbow, shoulder and foot fixation. The MODUS line combines products dedicated to cranio-maxillofacial (CMF) surgery. The Group's products are sold globally in more than 30 countries, including Germany and the United States, either directly through its sales subsidiaries, or through third-party distributors.
Medartis Holding AG operates as a medical device company. The company is headquartered in Basel, Basel-Stadt and currently employs 684 full-time employees. The company went IPO on 2018-03-23. The Group develops, manufactures and distributes to surgeons, hospitals and medical centers titanium screws, plates, surgical instruments and system solutions for internal fracture fixation. Medartis AG, the Company's wholly-owned subsidiary, has developed such technologies as TriLock for locking the screw into the plate, SpeedTip, a screw that does not require pre-drilling, and HexaDrive self-holding screw and screw-driver. The company has two product lines. The APTUS product line comprises upper and lower extremities products for hand, wrist, elbow, shoulder and foot fixation. The MODUS line combines products dedicated to cranio-maxillofacial (CMF) surgery. The Group's products are sold globally in more than 30 countries, including Germany and the United States, either directly through its sales subsidiaries, or through third-party distributors.
Strong Organic Growth: Medartis delivered 15.3% organic revenue growth in H1, exceeding expectations and hitting the upper end of guidance.
Guidance Raised: Full-year sales growth guidance increased to 14–16% as momentum continued into July and August.
Tariff Headwind Managed: US tariffs of 39% are expected to have a high single-digit million CHF impact by 2026, but management is mitigating through price increases, US production ramp-up, and cost controls.
Solid Margins Despite FX: Core gross margin held at 81% despite FX and tariff pressure; EBITDA margin slightly improved to 17.8%.
KeriMedical Acquisition Closed: Acquisition completed, with US launch of TOUCH prosthesis set for early 2025 and strong growth expected in Europe and new markets.
US and EMEA Outperformance: The US and EMEA regions both posted growth above 16%, with successful distributor optimization in the US.
Integration on Track: NeoOrtho integration in Brazil progressing smoothly; value and premium strategies remain separate in commercial focus.
